ENTRY       D00523                      Drug
NAME        Irbesartan (JP18/USP/INN);
            Avapro (TN)
PRODUCT     AVAPRO (Sanofi-Aventis U.S. LLC)
  GENERIC   IRBESARTAN (A-S Medication Solutions)
            IRBESARTAN (Alembic Pharmaceuticals Limited)
            IRBESARTAN (Alembic Pharmaceuticals)
            IRBESARTAN (Amneal Pharmaceuticals LLC)
            IRBESARTAN (Aurobindo Pharma Limited)
            IRBESARTAN (AvPAK)
            IRBESARTAN (Bryant Ranch Prepack)
            IRBESARTAN (Bryant Ranch Prepack)
            IRBESARTAN (Bryant Ranch Prepack)
            IRBESARTAN (Bryant Ranch Prepack)
            IRBESARTAN (Bryant Ranch Prepack)
            IRBESARTAN (Bryant Ranch Prepack)
            IRBESARTAN (Bryant Ranch Prepack)
            IRBESARTAN (Bryant Ranch Prepack)
            IRBESARTAN (Camber Pharmaceuticals)
            IRBESARTAN (Camber Pharmaceuticals)
            IRBESARTAN (DIRECTRX)
            IRBESARTAN (Hisun Pharmaceuticals USA)
            IRBESARTAN (Jubilant Cadista Pharmaceuticals)
            IRBESARTAN (Lupin Pharmaceuticals)
            IRBESARTAN (Macleods Pharmaceuticals Limited)
            IRBESARTAN (Proficient Rx LP)
            IRBESARTAN (Proficient Rx LP)
            IRBESARTAN (Proficient Rx LP)
            IRBESARTAN (Proficient Rx LP)
            IRBESARTAN (Proficient Rx LP)
            IRBESARTAN (Proficient Rx LP)
            IRBESARTAN (REMEDYREPACK)
            IRBESARTAN (REMEDYREPACK)
            IRBESARTAN (REMEDYREPACK)
            IRBESARTAN (REMEDYREPACK)
            IRBESARTAN (REMEDYREPACK)
            IRBESARTAN (ScieGen Pharmaceuticals)
            IRBESARTAN (Solco Healthcare U.S.)
            IRBESARTAN (Unichem Pharmaceuticals (USA))
            IRBESARTAN (Winthrop U.S.)
            IRBESARTAN (Zydus Lifesciences Limited)
            IRBESARTAN (Zydus Pharmaceuticals USA)
            IRBESARTAN (direct rx)
FORMULA     C25H28N6O
EXACT_MASS  428.2325
MOL_WEIGHT  428.5294
CLASS       Cardiovascular agent
             DG01925  Renin-angiotensin system inhibitor
              DG01495  Angiotensin II receptor antagonist
             DG03231  Antihypertensive
              DG01495  Angiotensin II receptor antagonist
            Metabolizing enzyme substrate
             DG01642  CYP2C9 substrate
REMARK      Same as: C07469
            Therapeutic category: 2149
            ATC code: C09CA04
            Product: D00523<JP/US>
            Product (mixture): D10243<JP> D10249<US> D10480<JP>
EFFICACY    Antihypertensive, Angiotensin II receptor antagonist
  DISEASE   Hypertension [DS:H01633]
            Nephropathy in type 2 diabetic [DS:H01456]
TARGET      AGTR1 [HSA:185] [KO:K04166]
  PATHWAY   hsa04080(185)  Neuroactive ligand-receptor interaction
            hsa04261(185)  Adrenergic signaling in cardiomyocytes
            hsa04270(185)  Vascular smooth muscle contraction
            hsa04614(185)  Renin-angiotensin system
METABOLISM  Enzyme: CYP2C9 [HSA:1559]
INTERACTION  
STR_MAP     map07229  Angiotensin receptor and endothelin receptor antagonists
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             C CARDIOVASCULAR SYSTEM
              C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
               C09C ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
                C09CA Angiotensin II receptor blockers (ARBs), plain
                 C09CA04 Irbesartan
                  D00523  Irbesartan (JP18/USP/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Cardiovascular Agents
              Angiotensin II Receptor Antagonists
               Irbesartan
                D00523  Irbesartan (JP18/USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              21  Cardiovascular agents
               214  Antihypertensives
                2149  Others
                 D00523  Irbesartan (JP18/USP/INN)
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01925  Renin-angiotensin system inhibitor
               DG01495  Angiotensin II receptor antagonist
                D00523  Irbesartan
              DG03231  Antihypertensive
               DG01495  Angiotensin II receptor antagonist
                D00523  Irbesartan
             Metabolizing enzyme substrate
              DG01642  CYP2C9 substrate
               D00523  Irbesartan
            Drug classes [BR:br08332]
             Cardiovascular agent
              DG01495  Angiotensin II receptor antagonist
               D00523  Irbesartan
              DG03231  Antihypertensive
               D00523  Irbesartan
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Angiotensin
                AGTR1
                 D00523  Irbesartan (JP18/USP/INN) &lt;JP/US&gt;
            Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
             Chemicals
              D00523  Irbesartan
              D00523  Irbesartan tablets
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D00523
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D00523
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D00523
DBLINKS     CAS: 138402-11-6
            PubChem: 7847589
            ChEBI: 5959
            LigandBox: D00523
            NIKKAJI: J549.417F
ATOM        32
            1   C8x C     5.1800  -12.9500
            2   C8x C     5.1800  -14.3500
            3   C8x C     6.3924  -15.0500
            4   C8x C     7.6049  -14.3500
            5   C8y C     7.6049  -12.9500
            6   C8y C     6.3924  -12.2500
            7   C8y C     8.8360  -12.2390
            8   C8x C    10.0412  -12.9347
            9   C8x C    11.2535  -12.2346
            10  C8y C    11.2535  -10.8346
            11  C8x C    10.0483  -10.1389
            12  C8x C     8.8359  -10.8390
            13  C8y C     6.3924  -10.8502
            14  N5x N     7.5103  -10.0378
            15  N5x N     7.0831   -8.7236
            16  N5x N     5.7012   -8.7237
            17  N4x N     5.2743  -10.0381
            18  C1b C    12.4714  -10.1312
            19  N1y N    13.6834  -10.8307
            20  C5x C    13.6834  -12.2307
            21  C1z C    15.0148  -12.6634
            22  N2x N    15.8378  -11.5307
            23  C2y C    15.0148  -10.3981
            24  O5x O    12.5198  -13.0762
            25  C1b C    15.0148   -8.9981
            26  C1b C    16.1875   -8.3215
            27  C1b C    17.3902   -9.0164
            28  C1x C    14.1834  -13.7856
            29  C1x C    14.9992  -14.9234
            30  C1x C    16.3334  -14.4992
            31  C1x C    16.3422  -13.0992
            32  C1a C    18.5743   -8.3332
BOND        36
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     5   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11   10  11 1
            12   11  12 2
            13    7  12 1
            14    6  13 1
            15   13  14 2
            16   14  15 1
            17   15  16 2
            18   16  17 1
            19   13  17 1
            20   10  18 1
            21   18  19 1
            22   19  20 1
            23   20  21 1
            24   21  22 1
            25   22  23 2
            26   19  23 1
            27   20  24 2
            28   23  25 1
            29   25  26 1
            30   26  27 1
            31   21  28 1
            32   28  29 1
            33   29  30 1
            34   30  31 1
            35   21  31 1
            36   27  32 1
///
